INMED PHARMACEUTICALS INC. Accounts Receivable, before Allowance for Credit Loss
INMED PHARMACEUTICALS INC. (INM) had Accounts Receivable, before Allowance for Credit Loss of $2.42 thousand as of 2025-06-30, per its S-4 filed 2026-07-02.
Financial Statements › Balance Sheet › Assets › Accounts Receivable, after Allowance for Credit Loss
us-gaap:AccountsReceivableGross · last filed 2026-07-02
- 2025-06-30: Accounts Receivable, before Allowance for Credit Loss $2.42K.
- 2024-06-30: Accounts Receivable, before Allowance for Credit Loss $0.00.
- 2023-06-30: Accounts Receivable, before Allowance for Credit Loss $66.78K.
| Period end | Accounts Receivable, before Allowance for Credit Loss |
|---|---|
| 2025-06-30 | $2.42K S-4 · filed 2026-07-02 |
| 2024-06-30 | $0.00 S-4 · filed 2026-07-02 |
| 2023-06-30 | $66.78K S-4 · filed 2026-07-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |